Myelosuppression in the Phase II and III studies with imatinib.
| . | Neutropenia . | Thrombocytopenia . | ||
|---|---|---|---|---|
| . | Grade 3 ANC < 1.0 x 109/L . | Grade 4 ANC < 0.5 x 109/L . | Grade 3 ANC < 50 x 109/L . | Grade 4 ANC < 10 x 109/L . |
| *ANC indicates absolute neutrophil count; IFN, interferon. | ||||
| Chronic phase (newly diagnosed) 26 | 11% | 2% | 7% | 0.5% |
| Chronic phase (IFN failure) 22 | 27% | 8% | 19% | 1% |
| Accelerated phase 23 | 23% | 35% | 31% | 12% |
| Blast crisis 24 | 16% | 48% | 29% | 33% |
| . | Neutropenia . | Thrombocytopenia . | ||
|---|---|---|---|---|
| . | Grade 3 ANC < 1.0 x 109/L . | Grade 4 ANC < 0.5 x 109/L . | Grade 3 ANC < 50 x 109/L . | Grade 4 ANC < 10 x 109/L . |
| *ANC indicates absolute neutrophil count; IFN, interferon. | ||||
| Chronic phase (newly diagnosed) 26 | 11% | 2% | 7% | 0.5% |
| Chronic phase (IFN failure) 22 | 27% | 8% | 19% | 1% |
| Accelerated phase 23 | 23% | 35% | 31% | 12% |
| Blast crisis 24 | 16% | 48% | 29% | 33% |